ADAP Advocacy Report Exposes Disparity in 340B Drug Pricing Program
ADAP Advocacy and CANN's report on the 340B Drug Pricing Program reveals concerning trends in executive compensation and patient care. Learn more about the impact of the findings and the call for transparency in healthcare.
This news sheds light on the potential misalignment of priorities within the 340B Program, raising questions about patient care versus financial gains. The findings underscore the need for transparency and accountability in healthcare organizations to ensure that the program benefits those it was intended to serve.
